HIGHLIGHTS
- who: Marion Mallet from the ErVaccine Technologies, Lyon, France have published the article: Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy, in the Journal: (JOURNAL)
- what: The authors propose that therapeutic should be considered in the context of low or moderate whereas Tg-T cell strategies may be more adapted for the treatment of advanced metastatic diseases. Based on the analysis of the dataset and the mathematical model, the authors propose to consider the total number of antigen-specific T_cells . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.